[Skip to Content]

Upstate Active Clinical Trials

Study Title:

A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanoma

Upstate Institutional Review Board (IRB) Number:

1387801

Study/Protocol ID:

APX005M-002

Patient Age Group:

Adults

Principal Investigator:

Stephen L Graziano, MD

Where will the study take place?

Upstate Cancer Center - All procedure
Med Onc Oswego and Oneida - consent only

Who can I contact for more information?

Name: Erinn Mcdowell, MS, CCRP
Phone: 315-464-8230
Email: mcdowele@upstate.edu

Return to Previous Page || Search Again

Top